Preconditioning of intravenous parecoxib attenuates focal cerebral ischemia/reperfusion injury in rats  被引量:9

Preconditioning of intravenous parecoxib attenuates focal cerebral ischemia/reperfusion injury in rats

在线阅读下载全文

作  者:WANG Na GUO Qu-lian YE Zhi XIA Ping-ping WANG E YUAN Ya-jing 

机构地区:[1]Department of Anesthesiology, Xiangya Hospital, Central SouthUniversity, Changsha, Hunan 410008, China

出  处:《Chinese Medical Journal》2011年第13期2004-2008,共5页中华医学杂志(英文版)

摘  要:Background Several studies suggest that cyclooxygenase-2 (COX-2) contributes to the delayed progression of ischemic brain damage. This study was designed to investigate whether COX-2 inhibition with parecoxib reduces focal cerebral ischemia/eperfusion injury in rats. Methods Ninety male Sprague-Dawley rats were randomly assigned to three groups: the sham group, ischemia/reperfusion (I/R) group and parecoxib group. The parecoxib group received 4 mg/kg of parecoxib intravenously via the vena dorsalis penis 15 minutes before ischemia and again at 12 hours after ischemia. The neurological deficit scores (NDSs) were evaluated at 24 and 72 hours after reperfusion. The rats then were euthanized. Brains were removed and processed for hematoxylin and eosin staining, Nissl staining, and measurements of high mobility group Box 1 protein (HMGB1) and tumor necrosis factor-α (TNF-α) levels. Infarct volume was assessed with 2,3,5-triphenyltetrazolium chloride (TTC) staining. Results The rats in the I/R group had lower NDSs (P 〈0.05), larger infarct volume (P 〈0.05), lower HMGB1 levels (P 〈0.05), and higher TNF-α levels (P 〈0.05) compared with those in the sham group. Parecoxib administration significantly improved NDSs, reduced infarct volume, and decreased HMGB1 and TNF-α levels (P 〈0.05). Conclusions Pretreatment with intravenous parecoxib was neuroprotective. Its effects may be associated with the attenuation of inflammatory reaction and the inhibition of inflammatory mediators.Background Several studies suggest that cyclooxygenase-2 (COX-2) contributes to the delayed progression of ischemic brain damage. This study was designed to investigate whether COX-2 inhibition with parecoxib reduces focal cerebral ischemia/eperfusion injury in rats. Methods Ninety male Sprague-Dawley rats were randomly assigned to three groups: the sham group, ischemia/reperfusion (I/R) group and parecoxib group. The parecoxib group received 4 mg/kg of parecoxib intravenously via the vena dorsalis penis 15 minutes before ischemia and again at 12 hours after ischemia. The neurological deficit scores (NDSs) were evaluated at 24 and 72 hours after reperfusion. The rats then were euthanized. Brains were removed and processed for hematoxylin and eosin staining, Nissl staining, and measurements of high mobility group Box 1 protein (HMGB1) and tumor necrosis factor-α (TNF-α) levels. Infarct volume was assessed with 2,3,5-triphenyltetrazolium chloride (TTC) staining. Results The rats in the I/R group had lower NDSs (P 〈0.05), larger infarct volume (P 〈0.05), lower HMGB1 levels (P 〈0.05), and higher TNF-α levels (P 〈0.05) compared with those in the sham group. Parecoxib administration significantly improved NDSs, reduced infarct volume, and decreased HMGB1 and TNF-α levels (P 〈0.05). Conclusions Pretreatment with intravenous parecoxib was neuroprotective. Its effects may be associated with the attenuation of inflammatory reaction and the inhibition of inflammatory mediators.

关 键 词:cerebral ischemia PARECOXIB neuropdotection INFLAMMATION 

分 类 号:R[医药卫生]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象